Alcoholic and nonalcoholic steatohepatitis

Clinics in Liver Disease

Volumn 6, Issue 2, 2002, Pages 399-420

  Brunt, Elizabeth M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; APOPTOSIS; DISEASE COURSE; FATTY LIVER; HEPATITIS; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; PATHOGENESIS; REVIEW; ALCOHOLIC FATTY LIVER; ARTICLE; DIFFERENTIAL DIAGNOSIS; HUMAN; LIVER; LIVER CIRRHOSIS; NECROSIS; PATHOLOGY; PROGNOSIS;

APOPTOSIS; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FATTY LIVER, ALCOHOLIC; HUMAN; LIVER; LIVER CIRRHOSIS; NECROSIS; PROGNOSIS; HUMANS;

EID: 0036311249     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00002-8     Document Type: Review

References (125)

1. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient
2. Recurrence of non-alcoholic steatohepatitis following liver transplantation
3. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation
4. Nonalcoholic steatohepatitis: Definition and pathology
5. Alcoholic liver disease: Morphological manifestations
6. Pathology of alcoholic liver disease
7. Histologic spectrum of alcoholic liver disease
8. Sclerosing hyaline necrosis in the liver of the chronic alcoholic. A recognizable lesion
9. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: Practical implications for the diagnosis of hemochromatosis
10. Hemosiderosis in cirrhosis: A study of 447 native livers
11. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis
12. Hemochromatosis: Diagnosis and management
13. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease
14. Fatty liver hepatitis and cirrhosis in obese patients
15. Liver injury with alcoholiclike hyaline after gastroplasty for morbid obesity
16. Hepatic lesions of central pericellular fibrosis in morbid obesity and after jejunoileal bypass
17. Post-jejunoileal bypass hepatic disease. Its similarity to alcoholic liver disease
18. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
19. The pathology of diabetic hepatitis
20. Subcapsular steatonecrosis in response to peritoneal insulin delivery: A clue to the pathogenesis of steatonecrosis in obesity
21. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity
22. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: Possible role in pseudoalcoholic liver lesions
23. Alcohol like liver disease in nonalcoholic patients a clinical and histologic comparison with alcohol-induced liver injury
24. Idiopathic steatohepatitis in childhood: A multicenter retrospective study
25. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
26. Nonalcoholic fatty liver disease: Assessment of variability in pathologic interpretations
27. Diagnosis and interpretation of steatosis and steatohepatitis
28. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis
29. Nonalcoholic steatohepatitis: A study of 49 patients
30. Two cases from the spectrum of nonalcoholic steatohepatitis
31. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
32. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
33. Clinical features and natural history of nonalcoholic steatosis syndromes
34. Non-alcoholic steatohepatitis in children and adults
35. Nonalcoholic steatohepatitis in children
36. Histopathology of community acquired chronic hepatitis C
37. The pathology of hepatitis C
38. Nonalcoholic steatohepatitis: An evolving diagnosis
39. Hepatic mitochondrial DNA deletion in alcoholic patients: Association with microvesicular steatosis
40. Mitochondria in steatohepatitis
41. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
42. Nonalcoholic steatohepatitis: Tightening the morphologic screws on a hepatic rambler
43. Prognostic factors in alcoholic liver disease
44. Metabolic liver diseases. Review: Nonalcoholic steatohepatitis
45. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosus
46. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis [color photomicrographs]
47. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis
48. Ultrastructural findings on polymorphonuclear leucocyte infiltration and acute hepatocellular damage in alcoholic hepatitis
49. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone
50. Fatty change and steatohepatitis
51. Mallory bodies revisited
52. Cytokeratin 8 protects from hepatotoxicity and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies
53. Apoptosis and alcoholic liver disease
54. Alcoholic liver disease
55. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver
56. Mitochondrial abnormalities in non-alcoholic steatohepatitis
57. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
58. Fatty liver and lesions in the alcoholic
59. Can steatohepatitis coexist with other forms of chronic liver disease?
60. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors
61. Hepatitis C virus antibody in alcoholic patients. Association with the presence of portal and/or lobular hepatitis
62. Chronic liver disease: Do alcohol and hepatitis C virus interact?
63. Liver biopsy findings in patients with alcoholic liver disease complicated by chronic hepatitis C virus infection
64. A histopathological study of alcoholic patients with chronic hepatitis C infection: Comparison with chronic hepatitis C and alcoholic liver disease
65. The intestinal and liver complications of diabetes mellitus
66. Pefisinusoidal fibrosis and basement membrane-like material in the livers of diabetic patients
67. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis
68. Hepatic stellate cell activation in non-alcoholic steatohepatitis and fatty liver
69. Alcoholic liver disease. Parenchyma to stroma relationship in fibrosis and cirrhosis as revealed by three-dimensional reconstruction and immunohistochemistry
70. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
71. Liver fibrosis in overweight patients
72. Classification of chronic viral hepatitis: A need for reassessment
73. Intraobserver and interobserver variations in live biopsies in patients with chronic hepatitis C
74. Diagnostic value of the fibrosis of the termmahepatic venule in fatty liver and chronic hepatitis due to ethanol or other aetiology
75. Hepatic vein lesions in alcoholic liver disease: Retrospective biopsy and necropsy study
76. Occlusive venous lesions in alcoholic liver disease
77. Early perivenular fibrogenesis - Pre-cirrhotic lesions among moderate alcohol consumers and chronic alcoholic patients
78. Nonalcoholic steatohepatitis clinicopathologic comparison with alcoholic hepatitis in ambulatory and hospitalized patients
79. Alcoholic hepatitis vs nonalcoholic steatohepatitis
80. Etiopathogenesis of nonalcoholic steatohepatitis
81. Classification of chronic hepatitis: Diagnosis, grading and staging
82. Day CP Who gets alcoholic liver disease: Nature or nurture?
83. Alcoholic liver disease
84. Alcoholic liver disease: Natural history
85. Promoter polymorphism of the CD 14 endotoxin receptor gene as a risk factor for alcoholic liver disease
86. Alcoholic liver disease
87. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease
88. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis
89. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis
90. The natural history of nonalcoholic fatty liver: A follow-up study
91. Natural history of alcoholic hepatitis III: Histologic changes
92. Nonalcoholic steatohepatitis
93. Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis
94. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance
95. Non-alcoholic steatohepatitis: Another disease of affluence
96. Body composition and hepatic steatosis as precursors for fibrosis in liver disease
97. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity
98. Nonalcoholic steatohepatitis: An expanded clinical entity
99. Nonalcoholic steatohepatitis a toxic liver disease in industrial workers
100. Non-alcoholic fatty liver: Another feature of the metabolic syndrome?
101. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?
102. Liver pathology in morbidly obese patients with and without diabetes
103. Insulin resistance and mitochondrial abnormalities in NASH: A cool look into a burning issue
104. Liver pathology and the metabolic syndrome X in severe obesity
105. Association of nonalcoholic fatty liver disease with insulin resistance
106. Treatment of nonalcoholic fatty liver: Present and emerging therapies
107. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
108. Diabetes mellitus and the liver
109. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
110. More clues to the relationship between hepatic iron and steatosis: An association with insulin resistance?
111. Insulin resistance-associated hepatic iron overload
112. NASH: Can we iron out the pathogenesis?
113. Hepatic iron and nonalcoholic fatty liver disease
114. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease
115. Nonalcoholic steatohepatitis
116. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Natural history?
117. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
118. Nonalcoholic steatohepatitis
119. Hepatic steatosis: Innocent bystander or guilty party?
120. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes
121. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
122. Is bacterial ASH the flash that ignites NASH?
123. Peroxisomal β oxidation and steatohepatitis
124. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
125. The role of small intestinal bacterial overgrowth, intestinal permeability endotoxemia, and tumour necrosis factor α in the path-genesis of non-alcoholic steatohepatitis